Although the minutes aren't out, I just noticed on the EMA...

Although the minutes aren't out, I just noticed on the EMA website they have highlights from the 22-25 April meeting

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/04/news_detail_001770.jsp&mid=WC0b01ac058004d5c1

The sole cryptic reference to our battered and bruised VG was:

"Organisational matters
Opinions on consultation procedures on ancillary medicinal substances in medical devices"

Interesting that it was under the heading "organisational matters". Suggests that the view that it was a matter for the MHRA may have some resonance. At least we aren't a medicine... yet...

The fact that no mention was made of VG though is disappointing and suggests that discussions are still proceeding. The depressing reality is that even if we get a positive outcome, we will be immediately clobbered by another fund-raising, so it is unlikely that we will be getting any significant buying when the downside risk is high and the upside not necessarily great in the short term.

How I wish I had never tipped so much of my hard-earned into this....